Oncology

Apollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apollomics has developed a pipeline of small molecules and monoclonal antibodies.  Apollomics has raised USD 100 million in a series B. Pear Therapeutics raises USD 64 Million San Francisco based Pear Therapeutics has raised USD 64 million for its prescription software to treat opioid disorder. The reSET-O prescription digital therapeutic for opioid ...